臨床不適任調度單

 【不適任人員處理紀錄 - 臨床安全指標】

1. 具體事實：針頭未依規範棄置於銳器盒（感控紅線）。

2. 設備整備疏失：急救耗材（氧氣瓶）及監測儀器（心電圖機）電力未落實點班巡檢。

3. 藥事安全：藥車品項混亂，未落實過期藥物報廢程序。

4. 輔導成效：經多次口頭指導及現場糾正，仍未見行為改善。

5. 結論：評估該員缺乏臨床警覺性（Clinical Vigilance），具高度醫療風險，建議予以淘汰或轉任非臨床單位。

four score

 def generate_four_score_order(eye, motor, brainstem, respiration):

    """

    生成 FOUR Score 專業醫囑描述

    """

    total = eye + motor + brainstem + respiration

    

    # FOUR 指數各項定義 (人話翻譯)

    summary = f"FOUR Score: E{eye}M{motor}B{brainstem}R{respiration}, Total: {total}/16"

    

    order_text = f"請醫師根據以下數據調整醫囑：\n{summary}\n"

    order_text += "備註：本單位已採用 FOUR Score 進行神經學評估，聽不懂請自行查閱最新重症護理指引。"

    

    return order_text

# 範例：一個插管且腦幹反射尚存的病人

print(generate_four_score_order(eye=2, motor=3, brainstem=4, respiration=2))

內科醫療縮寫

 醫療縮寫,臨床意義,對家屬的「人話」解釋

Code Blue,心肺功能停止,「病人現在突然沒呼吸心跳了，我們正在全力急救。」

Intubation,氣管內插管,「他的呼吸太喘、撐不住了，我們必須幫他插管、接上呼吸器代替他呼吸。」

DNR,放棄急救同意書,「如果病人到最後撐不住，我們是不是不要再讓他受苦（壓胸、電擊），讓他平靜地走？」

Septic Shock,敗血性休克,「病人的細菌感染太嚴重，毒素流進血液，導致血壓掉到危險邊緣，器官快要撐不住了。」

GCS 下降,昏迷指數下降,「病人的意識越來越不清楚，現在叫他也沒反應，代表大腦或身體狀況在惡化。」

Transfer to ICU,轉入加護病房,「病房現在的儀器不夠用了，我們要把他轉到加護病房，讓專門的團隊 24 小時盯著他。」

內科藥物機轉和衝突

 【Interaction: Warfarin & Antibiotics】

1. Mechanism: Displacement from albumin binding or inhibition of Cytochrome P450 (CYP) enzymes.

2. High-Risk Agents: Quinolones, Macrolides, and Sulfonamides (Baktar).

3. Clinical Impact: Elevated INR, increased risk of spontaneous bleeding (ICH, GI bleeding).

4. NP Intervention: Monitor INR frequently, consider prophylactic dose reduction, and switch to safer antibiotic options if possible.

【Interaction: Diuretics & Digoxin/Anti-arrhythmics】

1. Mechanism: Hypokalemia (induced by Loop diuretics like Lasix) sensitizes the myocardium to Digoxin.

2. Clinical Impact: Digoxin toxicity (N/V, blurred vision, life-threatening arrhythmias).

3. QT Prolongation: Combined use of Macrolides and certain antipsychotics (e.g., Haloperidol) increases risk of Torsades de Pointes (TdP).

4. NP Intervention: Monitor Serum K+ and Mg2+ levels; perform baseline and follow-up ECG to measure QTc intervals.

【Interaction: Statins & CYP Inhibitors】

1. Mechanism: Inhibition of CYP3A4 leads to elevated Statin serum levels.

2. Culprits: Grapefruit juice, Amiodarone, Diltiazem, and some Antifungals.

3. Clinical Impact: Rhabdomyolysis (muscle pain, tea-colored urine, acute renal failure).

4. NP Intervention: Educate patient on diet; assess CPK levels if muscle pain is reported.

內科專科護理師指引

 【Sepsis Management - SSC 2021 Guidelines】

1. Implementation of Hour-1 Bundle: Initial lactate level measurement, obtaining blood cultures prior to administration of broad-spectrum antibiotics.

2. Fluid Resuscitation: For patients with sepsis-induced hypoperfusion or lactate ≥4 mmol/L, administer at least 30 mL/kg of IV crystalloid fluid within the first 3 hours.

3. Vasopressors: If MAP remains <65 mmHg despite fluid resuscitation, initiate norepinephrine as the first-line vasopressor.

4. Continuous Monitoring: Re-assess fluid status and tissue perfusion (MAP, Urine Output, Lactate clearance).

【AECOPD Management - GOLD 2024 Guidelines】

1. Oxygen Therapy: Target SpO2 maintained at 88-92% to prevent hypercapnic respiratory failure.

2. Pharmacological Intervention: Short-acting inhaled beta2-agonists (SABA) with/without anticholinergics (SAMA). 

3. Systemic Therapy: Consider systemic corticosteroids (e.g., Prednisolone 40mg QD for 5 days) and antibiotics if increased sputum purulence/volume.

4. Respiratory Support: Early initiation of Non-invasive Ventilation (NIV/BiPAP) if respiratory acidosis (pH < 7.35 or PaCO2 > 45 mmHg).

【Heart Failure Management - 2022 AHA/ACC/HFSA Guidelines】

1. GDMT Optimization: Implementation of four pillar therapies for HFrEF patients:

   - ARNI (Sacubitril/Valsartan) or ACEI/ARB

   - Evidence-based Beta-blockers (Carvedilol, Bisoprolol, or Metoprolol succinate)

   - Mineralocorticoid Receptor Antagonists (MRA)

   - SGLT2 Inhibitors (Dapagliflozin or Empagliflozin)

2. Monitoring: Evaluate renal function (BUN/Cr), electrolytes (K+), and blood pressure titration during the stabilization phase.

【Diabetes Care - ADA 2024 Standards of Care】

1. Organ Protection Strategy: For patients with established ASCVD, Heart Failure, or CKD, prioritize SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular/renal benefit.

2. Glycemic Targets: Individualized A1c goals (usually <7% for most non-pregnant adults) balanced with hypoglycemia risk assessment.

3. Screening: Annual monitoring of UACR (Urine Albumin-to-Creatinine Ratio) and eGFR for early detection of diabetic kidney disaese.

【NP Clinical Decision Framework】

1. Initial Assessment: Focused physical examination and review of vital signs (Identify Red Flags).

2. Diagnostic Logic: Review lab results (ABG, CXR, ECG) based on evidence-based guidelines (e.g., GOLD, SSC, AHA).

3. Collaborative Decision: Propose a pre-settled order or medical plan (Pharmacological + Non-pharmacological).

4. Monitoring & Follow-up: Evaluate patient response and adjust the management plan to optimize outcomes and reduce ALOS (Average Length of Stay).

GCS and four compare

 ===========================================================

        內科病房意識評估與預警攔截單 (Double Check 版)

===========================================================

日期：2026 / ____ / ____ 時間：________ 病床號：________

評估人員 A：________________ 評估人員 B (複核)：________________

-----------------------------------------------------------

【第一部分：GCS 溝通碼】(通報醫師使用)

■ [E] 睜眼反應 ■ [V] 語言反應 ■ [M] 動作反應

□ 4 - 自然睜眼 □ 5 - 定向感正確 □ 6 - 遵照指令

□ 3 - 呼喚睜眼 □ 4 - 答非所問/混亂 □ 5 - 痛覺定位 (能撥開)

□ 2 - 痛覺睜眼 □ 3 - 僅能說出單字 □ 4 - 痛覺縮回 (僅縮手)

□ 1 - 無反應 □ 2 - 僅能發出聲音 □ 3 - 異常屈曲

                         □ 1 - 無反應 □ 2 - 異常伸展

                                                  □ 1 - 無反應

-----------------------------------------------------------

GCS 總分：________ / 15 (若 ≦ 8 分，請立即通報急救插管)

===========================================================

【第二部分：FOUR Score 攔截指標】(內部預警與提早攔截用)

■ [E] 眼神追蹤 (關鍵指標) ■ [B] 腦幹反射 (深度指標)

□ 4 - 眼神可隨手指追蹤 □ 4 - 瞳孔/角膜反射皆正常

□ 3 - 睜眼但無法追蹤 □ 3 - 單側瞳孔放大/固定

□ 2 - 叫才睜眼 □ 2 - 瞳孔對光反射消失

□ 1 - 痛才睜眼 □ 1 - 角膜反射消失

□ 0 - 完全不開 □ 0 - 兩者反射皆消失

■ [M] 動作指令 ■ [R] 呼吸模式 (最速攔截點！)

□ 4 - 能比「OK/讚/耶」 □ 4 - 呼吸節律穩定規律

□ 3 - 痛覺定位 □ 3 - 喘/過度換氣 (RR > 30) ➔【黃燈】

□ 2 - 痛覺縮回 □ 2 - 呼吸節律不規則/深淺不一

□ 1 - 異常姿勢 (屈曲/伸展) □ 1 - 與呼吸器對抗 (已插管者)

□ 0 - 完全不動 □ 0 - 無自主呼吸/完全依賴機器

===========================================================

【指揮官處置建議 (Better Safe Than Sorry)】

1. 任何一項出現「下墜斜率」(如 R4 變 R3)，請啟動 Double Check。

2. 若呼吸模式 (R) ≦ 3 分，即便 GCS 15 分，亦須評估 ABG/Oxygen 需求。

3. 若醫師拒絕到場評估，請於護理紀錄註明：「經雙人評估 FOUR Score 異常並通報醫師，MD 指示持續觀察」。

===========================================================

內科送ICU order

### [ICU Transfer Note / STAT Order]

**1. Transfer Diagnosis & Indication (轉科原因與適應症)**

- Impending Respiratory Failure (即將發生的呼吸衰竭)

- Altered Mental Status (意識狀態改變/Coma)

**2. Clinical Event Timeline (事件精準時間線 - 防禦性紀錄)**

- 11:15 AM: SpO2 dropped from 92% to 90%. Informed Primary MD. 

- [Note]: Per MD instruction, "Observation only if SpO2 < 90%". (醫囑備註：醫師要求90%以下再開始觀察)

- 11:20 AM: SpO2 dropped to 88%. Patient showed respiratory distress & paradoxical breathing.

- 11:22 AM: Escalated O2 therapy to Non-rebreather mask (15L/min). 

- 11:25 AM: Urgently paged MD again. MD arrived at 11:35 AM for evaluation.

- 11:45 AM: Patient mental status progressed to Coma. Initiated ICU transfer protocol.

**3. Current Respiratory Support (目前呼吸支持)**

- O2 Device: Non-rebreather Mask @ 15L/min.

- Airway: Oropharyngeal airway (OPA) inserted. Suctioned moderate thick yellowish secretion.

- SpO2: 88-90% (Under high-flow O2).

**4. Final Vital Signs (離開病房前最後快照)**

- T/P/R: 37.2 / 128 / 32 (Tachypnea)

- BP: 165/98 mmHg

- GCS: E2V1M4 (Coma scale)

**5. Tubes & Access (管路與治療)**

- IV Access: 20G on Left forearm (Patent).

- Tubes: N-G tube (Room drainage), Foley catheter (Patent).

- Meds: All routine meds held due to acute change.

**6. Pending Issues (待追蹤事項)**

- ABG (Arterial Blood Gas) drawn at 11:40 AM - Result Pending.

- Family notified about the critical condition and ICU transfer.